Qiagen (QGEN) Receives a Hold from Kepler Capital
In a report released yesterday, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen (QGEN), with a price target of EUR39.00. The company’s shares closed last Monday at $39.86.
According to TipRanks.com, Pataki is a 1-star analyst with an average return of -8.7% and a 31.6% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Tecan Group AG, and Alcon.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $36.10 average price target.
See today’s analyst top recommended stocks >>
Based on Qiagen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $413 million and net profit of $44.93 million. In comparison, last year the company earned revenue of $403 million and had a net profit of $60.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.